

Message

---

**From:** Ex. 6 Personal Privacy (PP)  
**Sent:** 4/6/2020 1:03:26 PM  
**To:** Ex. 6 Personal Privacy (PP)  
**CC:**  
**Subject:** Re: MCAN issue - potentially needs elevation to management

Ex. 6 Personal Privacy (PP) still has some reservations but is willing to not call it incomplete at this time. She is reserving the right to call it incomplete later if RAD will not accept ICB's report. So, let's proceed.

Sent from my iPhone

On Apr 6, 2020, at 8:53 AM, Ex. 6 Personal Privacy (PP) wrote:

Morning Ex. 6 Personal Privacy (PP)

I just wanted to make sure that we were in good standing to not call this incomplete. Ex. 6 Personal Privacy (PP) didn't seem particularly convinced, so I wanted to get the greenlight before I passed the plan on to the biotech team/let the submitter know.

Thanks,

Ex. 6 Personal Privacy (PP)

---

**From:** Ex. 6 Personal Privacy (PP)

**Sent:** Thursday, April 02, 2020 9:57 PM

**To:** Ex. 6 Personal Privacy (PP)

**Cc:**

**Subject:** Re: MCAN issue - potentially needs elevation to management

Thanks Ex. 6 Personal Privacy (PP)

Ex. 6 Personal Privacy (PP) if you are in tomorrow and were cc'd on Ex. 6 Personal Privacy (PP) CBI email, please forward it to Ex. 6 Personal Privacy (PP) I am off tomorrow and may not have ready access to my computer.

Sent from my iPhone

On Apr 2, 2020, at 7:55 PM, Ex. 6 Personal Privacy (PP) wrote:

I sent you a cbi email to let this one go through (for now).

---

**From:** Ex. 6 Personal Privacy (PP)

**Sent:** Thursday, April 2, 2020 4:20 PM

**To:** Ex. 6 Personal Privacy (PP)

**Subject:** Fw: MCAN issue - potentially needs elevation to management

Ex. 5 Personal Privacy (PP)

I sent an email to you on the CBI side yesterday about this case. It has become a "hair on fire" case because the submitter appears to be willing to complain to senior mgmt. if we issue an incomplete letter. Please read the email below. I will try calling you.

From: **Ex. 6 Personal Privacy (PP)**

Sent: Thursday, April 2, 2020 3:26 PM

To: **Ex. 6 Personal Privacy (PP)**

Subject: FW: MCAN issue - potentially needs elevation to management

Ex. 5 Personal Privacy (PP) could you give Ex. 6 Personal Privacy (PP) a call about this?

---

From: **Ex. 6 Personal Privacy (PP)**

Sent: Thursday, April 02, 2020 2:04 PM

To: **Ex. 6 Personal Privacy (PP)**

<

Subject: MCAN issue - potentially needs elevation to management

Hi **Ex. 6 Personal Privacy (PP)**

## Ex. 5 Deliberative Process (DP)

Sincerely,

Ex. 5 Personal Privacy (PP)

---

From: Chen, Alice <Alice.Chen-1@dupont.com>

Sent: Thursday, April 2, 2020 11:16 AM

To: **Ex. 6 Personal Privacy (PP)**

**Cc:** GRIECO, LIANE M <Liane.M.Grieco@dupont.com>

**Subject:** RE: Update on MCAN

Hi  Ex: Personal Privacy (PP)

Would it be possible for EPA to provide a technical basis (e.g., literature citations) to substantiate their position that when an *S. cerevisiae* is crossed with another *S. cerevisiae* (both parents with taxonomic substantiation that is acknowledged by EPA) that the resulting progeny is not *S. cerevisiae*? We would be happy to provide several literature citations (likely in the thousands) to demonstrate that when two of the same species are mated, the same species results. Therefore, there is a technical position heavily supported by the scientific community that the GPY10145 will be *S. cerevisiae*, and that there is sufficient information provided in the MCAN for EPA to make this determination. Direct information on GPY10145 is therefore not needed in this case, although DuPont is communicating that we have direct evidence on GPY10145 that we working on to provide to EPA. In addition, we have information in the MCAN supporting through phenotypic characterization in Section 5.2.1 that the resulting new microorganisms behave like *S. cerevisiae*.

Would EPA like to have a call with our R&D team to understand how crosses between the same species results in the same species? Otherwise, if EPA moves forward with a decision to consider this submission incomplete, we will contact EPA upper management to discuss this issue as there is sufficient information in the MCAN to make the determination that the recipient strain is *S. cerevisiae*. Please let me know if you have any further concerns or questions.

Best regards,  
Alice

Alice Chen, Ph.D.  
Senior Manager for North America, Regulatory Affairs and Product Stewardship  
**DuPont Nutrition and Biosciences**

<image001.png>  
Danisco US Inc. | 925 Page Mill Road | Palo Alto, CA 94304  
📠 office 650-846-5866 | 📞 cell 650-422-0356 | ✉: [alice.chen-1@dupont.com](mailto:alice.chen-1@dupont.com)